Virometix AG
https://www.virometix.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Virometix AG
Finance Watch: Venture Capital Funders Raise Billions For Biotech Investments
Private Company Edition: Forbion closed two funds totaling €1.35bn ($1.5bn) and Glide Healthcare raised €600m ($657.5m) for its latest fund, joining recent venture capital raises by Lux Capital and Wellington Management, but in the first quarter biopharma VC company financings fell dramatically.
Allergy Therapeutics Takes First Steps Into Broader Vaccine Field
Allergy Therapeutics is keen to extend its early R&D pipeline into non-allergy areas through extending its tie-up with Saiba and DeepVax on their virus-like particle technology.
Anergis And Virometix Collaborate On Fast-Acting Allergy Immunotherapy
An ultra-fast-acting allergy immunotherapy to induce tolerance to house dust mites is being sought in a collaboration between two Swiss biotechs, Anergis and Virometix.
Medtech Execs On The Move, January 2016
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
- Vaccines
-
Biotechnology
-
Drug Discovery Tools
- ADMET
-
Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice